Show simple item record

dc.contributor.authorSilva, H. T.
dc.contributor.authorFelipe, C. R.
dc.contributor.authorMachado, PGP
dc.contributor.authorGarcia, R.
dc.contributor.authorMotegi, S.
dc.contributor.authorHosaka, B. H.
dc.contributor.authorHanzawa, N. M.
dc.contributor.authorPark, S. I.
dc.contributor.authorCasarini, D.
dc.contributor.authorLima, V. C.
dc.contributor.authorFranco, M.
dc.contributor.authorMedina-Pestana, J. O.
dc.date.accessioned2016-01-24T12:33:49Z
dc.date.available2016-01-24T12:33:49Z
dc.date.issued2003-05-01
dc.identifierhttp://dx.doi.org/10.1016/S0041-1345(03)00232-X
dc.identifier.citationTransplantation Proceedings. New York: Elsevier B.V., v. 35, n. 3A, p. 177S-180S, 2003.
dc.identifier.issn0041-1345
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/27231
dc.description.abstractWe show the key results of our 4-year experience with sirolimus in kidney transplant patients and in nontransplanted patients undergoing coronary angioplasty.Methods: Recipients of one-haplotype living-related kidney allografts were randomized to receive sirolimus (2 mg/d, n = 35) or azathioprine (2 mg/kg per day, n = 35). Recipients of fully mismatched living kidney allografts (n = 55) received sirolimus (2 mg/day). High-risk recipients of black ethnicity (n = 68) were randomized to target whole-blood trough sirolimus concentrations between 8 and 12 ng/mL or 15 to 20 ng/mL. All kidney transplant patients received cyclosporine and prednisone. Sirolimus/cyclosporine pharmacokinetic studies were performed in 40 patients receiving 2 mg (n = 20) or 5 mg (n = 20) of sirolimus 7 days after transplantation. in the coronary intervention study, 12 patients at high risk for in-stent restenosis received sirolimus for 28 days after angioplasty.Results: the incidence of biopsy-confirmed acute rejection was 11.4% in recipients of one-haplotype. living-related kidney allografts, 16.4% in recipients of fully mismatched living kidney allografts, and 15% (8 to 12 ng/mL) and 4% (15 to 20 ng/mL) in high-risk recipients of black ethnicity. Cyclosporine exposure was higher after morning administration compared to evening administration. There were poor correlations between sirolimus and cyclosporine exposures. the 4-month follow-up angiography revealed no restenosis (stenosis diameter > 50%), a late loss of 0.56 +/- 0.40 mm, and a loss index of 0.33 +/- 0.30. the follow-up 3D-intravascular ultrasound restudy showed an in-stent relative volumetric obstruction of 9.9 +/- 5.5%. Sirolimus in highly effective in preventing kidney allograft acute rejection and in-stent coronary restenosis.en
dc.format.extent177S-180S
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.ispartofTransplantation Proceedings
dc.rightsAcesso restrito
dc.titleSafety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplastyen
dc.typeArtigo
dc.rights.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.description.affiliationUniversidade Federal de São Paulo, Hosp Rim & Hipertensao, Div Nephrol, BR-04038002 São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Hosp Rim & Hipertensao, Div Nephrol, BR-04038002 São Paulo, Brazil
dc.identifier.doi10.1016/S0041-1345(03)00232-X
dc.description.sourceWeb of Science
dc.identifier.wosWOS:000182991100035


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record